omeprazole has been researched along with Hepatocellular Carcinoma in 11 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on clearance of CYP isoform-specific substrates at the microsomal level (CLM), microsomal protein per gram of liver (MPPGL), liver weight, hepatic blood flow, hepatic clearance values (CLH) for 10 CYPs in HCC patients (n=102) were extrapolated using a predictive bottom-up pharmacokinetic model." | 1.43 | Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach. ( Fang, Y; Gao, J; Gao, N; He, XP; Jia, LJ; Jin, H; Qiao, HL; Tian, X; Wen, Q; Zhang, YF; Zhou, J, 2016) |
| "Omeprazole is a drug used for treating gastro-oesophageal reflux disease and duodenal ulcers." | 1.35 | Omeprazole alleviates benzo[a]pyrene cytotoxicity by inhibition of CYP1A1 activity in human and mouse hepatoma cells. ( Kawanishi, M; Ohsako, S; Shiizaki, K; Yagi, T, 2008) |
| "Omeprazole is a well known activator of the aryl hydrocarbon receptor (AhR)." | 1.33 | Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. ( Daujat-Chavanieu, M; Fabre, JM; Gerbal-Chaloin, S; Maurel, P; Pichard-Garcia, L; Poellinger, L; Sa-Cunha, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chintalapati, SP | 1 |
| Patel, A | 1 |
| Conjeevaram, H | 1 |
| Gao, J | 1 |
| Zhou, J | 1 |
| He, XP | 1 |
| Zhang, YF | 1 |
| Gao, N | 1 |
| Tian, X | 1 |
| Fang, Y | 1 |
| Wen, Q | 1 |
| Jia, LJ | 1 |
| Jin, H | 1 |
| Qiao, HL | 1 |
| Shiizaki, K | 1 |
| Ohsako, S | 1 |
| Kawanishi, M | 1 |
| Yagi, T | 1 |
| Backlund, M | 1 |
| Ingelman-Sundberg, M | 1 |
| Gerbal-Chaloin, S | 1 |
| Pichard-Garcia, L | 1 |
| Fabre, JM | 1 |
| Sa-Cunha, A | 1 |
| Poellinger, L | 1 |
| Maurel, P | 1 |
| Daujat-Chavanieu, M | 1 |
| Trubetskoy, O | 1 |
| Marks, B | 1 |
| Zielinski, T | 1 |
| Yueh, MF | 1 |
| Raucy, J | 1 |
| Yoshinari, K | 1 |
| Ueda, R | 1 |
| Kusano, K | 1 |
| Yoshimura, T | 1 |
| Nagata, K | 1 |
| Yamazoe, Y | 1 |
| Kikuchi, H | 3 |
| Hossain, A | 3 |
| Sagami, I | 1 |
| Ikawa, S | 2 |
| Watanabe, M | 2 |
| Kato, H | 1 |
| Mizuno, M | 1 |
| Miyazaki, J | 1 |
| Yoshida, H | 1 |
| Kobayashi, S | 1 |
| de Mestier, P | 1 |
11 other studies available for omeprazole and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Gastric and duodenal ischaemia after transarterial chemoembolisation for hepatocellular carcinoma: an unexpected but significant complication.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Duodenum; Gastrointestinal Hemorrhage; Hu | 2018 |
Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.
Topics: Algorithms; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; GABA Modulators; Humans; Isoe | 2016 |
Omeprazole alleviates benzo[a]pyrene cytotoxicity by inhibition of CYP1A1 activity in human and mouse hepatoma cells.
Topics: Animals; Anti-Ulcer Agents; Benzo(a)pyrene; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome | 2008 |
Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases.
Topics: Amino Acid Substitution; Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Genistein; | 2005 |
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide.
Topics: Active Transport, Cell Nucleus; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Culture | 2006 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytoch | 2005 |
Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements.
Topics: Carcinoma, Hepatocellular; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Enzyme Induction; Human | 2008 |
Different inducibility of cytochrome P-4501A1 mRNA of human and mouse by omeprazole in culture cells.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Nucleus; Cytochrome P-450 Enzyme System; Gen | 1995 |
Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Li | 1996 |
Induction of cytochrome P-450 1A1 by omeprazole in human HepG2 cells is protein tyrosine kinase-dependent and is not inhibited by alpha-naphthoflavone.
Topics: Benzoflavones; Benzoquinones; Carcinoma, Hepatocellular; Cytochrome P-450 CYP1A1; DNA Topoisomerases | 1998 |
[Congress of the American College of Surgeons (ACS). San Francisco, 10-15 October 1999].
Topics: Anti-Ulcer Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholang | 1999 |